158 related articles for article (PubMed ID: 34972788)
1. Successful treatment of pituitary gigantism.
Cunha C; Saraiva C; Canas Marques C; Duarte JS
BMJ Case Rep; 2021 Dec; 14(12):. PubMed ID: 34972788
[TBL] [Abstract][Full Text] [Related]
2. Gigantism caused by growth hormone secreting pituitary adenoma.
Rhee N; Jeong K; Yang EM; Kim CJ
Ann Pediatr Endocrinol Metab; 2014 Jun; 19(2):96-9. PubMed ID: 25077093
[TBL] [Abstract][Full Text] [Related]
3. Spontaneous remission of acromegaly or gigantism due to subclinical apoplexy of pituitary growth hormone adenoma.
Wang XL; Dou JT; Lü ZH; Zhong WW; Ba JM; Jin D; Lu JM; Pan CY; Mu YM
Chin Med J (Engl); 2011 Nov; 124(22):3820-3. PubMed ID: 22340248
[TBL] [Abstract][Full Text] [Related]
4. Pegvisomant therapy in pituitary gigantism: successful treatment in a 12-year-old girl.
Rix M; Laurberg P; Hoejberg AS; Brock-Jacobsen B
Eur J Endocrinol; 2005 Aug; 153(2):195-201. PubMed ID: 16061823
[TBL] [Abstract][Full Text] [Related]
5. Five-year follow-up of a 13-year-old boy with a pituitary adenoma causing gigantism--effect of octreotide therapy.
Schoof E; Dörr HG; Kiess W; Lüdecke DK; Freitag E; Zindel V; Rascher W; Dötsch J
Horm Res; 2004; 61(4):184-9. PubMed ID: 14739526
[TBL] [Abstract][Full Text] [Related]
6. A legendary sumo wrestler with gigantism or acromegaly? The case of Ikezuki Geitazaemon (1827-1850).
Takada K; Sasano M; Hayakawa S
Med Hypotheses; 2020 Nov; 144():110174. PubMed ID: 33254497
[TBL] [Abstract][Full Text] [Related]
7. Impact of tumor characteristics and pre- and postoperative hormone levels on hormonal remission following endoscopic transsphenoidal surgery in patients with acromegaly.
Cardinal T; Rutkowski MJ; Micko A; Shiroishi M; Jason Liu CS; Wrobel B; Carmichael J; Zada G
Neurosurg Focus; 2020 Jun; 48(6):E10. PubMed ID: 32480366
[TBL] [Abstract][Full Text] [Related]
8. Pituitary gigantism: a rare learning opportunity.
Bendor-Samuel OM; Pal A; Cudlip S; Anderson G; Salgia S; Makaya T
Arch Dis Child Educ Pract Ed; 2020 Apr; 105(2):111-116. PubMed ID: 30948480
[TBL] [Abstract][Full Text] [Related]
9. Transsphenoidal microsurgery in the treatment of acromegaly and gigantism.
Arafah BU; Brodkey JS; Kaufman B; Velasco M; Manni A; Pearson OH
J Clin Endocrinol Metab; 1980 Mar; 50(3):578-85. PubMed ID: 6244327
[TBL] [Abstract][Full Text] [Related]
10. Pegvisomant treatment in gigantism caused by a growth hormone-secreting giant pituitary adenoma.
Müssig K; Gallwitz B; Honegger J; Strasburger CJ; Bidlingmaier M; Machicao F; Bornemann A; Ranke MB; Häring HU; Petersenn S
Exp Clin Endocrinol Diabetes; 2007 Mar; 115(3):198-202. PubMed ID: 17427111
[TBL] [Abstract][Full Text] [Related]
11. The utility of oral glucose tolerance testing for diagnosis and assessment of treatment outcomes in 166 patients with acromegaly.
Carmichael JD; Bonert VS; Mirocha JM; Melmed S
J Clin Endocrinol Metab; 2009 Feb; 94(2):523-7. PubMed ID: 19033371
[TBL] [Abstract][Full Text] [Related]
12. Cardiac and metabolic effects of chronic growth hormone and insulin-like growth factor I excess in young adults with pituitary gigantism.
Bondanelli M; Bonadonna S; Ambrosio MR; Doga M; Gola M; Onofri A; Zatelli MC; Giustina A; degli Uberti EC
Metabolism; 2005 Sep; 54(9):1174-80. PubMed ID: 16125529
[TBL] [Abstract][Full Text] [Related]
13. Acromegaly with initial negative oral glucose tolerance test: a case report.
Tsai WH; Chien MN; Dai SH; Chan YK
J Med Case Rep; 2023 Aug; 17(1):333. PubMed ID: 37543629
[TBL] [Abstract][Full Text] [Related]
14. Large-scale second-hit AIP deletion causing a pediatric growth hormone-secreting pituitary adenoma: Case report and review of literature.
Gummadavelli A; Dinauer C; McGuone D; Vining EM; Erson-Omay EZ; Omay SB
J Clin Neurosci; 2020 Aug; 78():420-422. PubMed ID: 32336638
[TBL] [Abstract][Full Text] [Related]
15. A novel truncating AIP mutation, p.W279*, in a familial isolated pituitary adenoma (FIPA) kindred.
Cansu GB; Taşkıran B; Trivellin G; Faucz FR; Stratakis CA
Hormones (Athens); 2016 Jul; 15(3):441-444. PubMed ID: 27838609
[TBL] [Abstract][Full Text] [Related]
16. Efficacy, safety, and pharmacokinetics of sustained-release lanreotide (lanreotide Autogel) in Japanese patients with acromegaly or pituitary gigantism.
Shimatsu A; Teramoto A; Hizuka N; Kitai K; Ramis J; Chihara K
Endocr J; 2013; 60(5):651-63. PubMed ID: 23337477
[TBL] [Abstract][Full Text] [Related]
17. Congenital gigantism due to growth hormone-releasing hormone excess and pituitary hyperplasia with adenomatous transformation.
Zimmerman D; Young WF; Ebersold MJ; Scheithauer BW; Kovacs K; Horvath E; Whitaker MD; Eberhardt NL; Downs TR; Frohman LA
J Clin Endocrinol Metab; 1993 Jan; 76(1):216-22. PubMed ID: 8421089
[TBL] [Abstract][Full Text] [Related]
18. Delayed diagnosis of acromegaly in a patient with focal segmental Glomerulosclerosis: a rare case report and literature review.
Zheng J; Cui Z; Lv JC; Duan HZ; Wang SX; Zhang JQ; Zhou FD; Guo XH; Zhao MH
BMC Nephrol; 2019 Nov; 20(1):435. PubMed ID: 31771524
[TBL] [Abstract][Full Text] [Related]
19. Clinical, hormonal and magnetic resonance imaging (MRI) predictors of transsphenoidal surgery outcome in acromegaly.
Bourdelot A; Coste J; Hazebroucq V; Gaillard S; Cazabat L; Bertagna X; Bertherat J
Eur J Endocrinol; 2004 Jun; 150(6):763-71. PubMed ID: 15191345
[TBL] [Abstract][Full Text] [Related]
20. Pituitary gigantism causing diabetic ketoacidosis.
Alvi NS; Kirk JM
J Pediatr Endocrinol Metab; 1999; 12(6):907-9. PubMed ID: 10614552
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
